Mutares Pins Its Second-Half Recovery on a Czech Chemical Deal and a 100 Million Euro Exit

Mutares' H1 adjusted EBITDA swings to €67M, but shares fall 14% YTD as investors await exits and consolidation gains.

The market's verdict on Mutares' latest earnings report was a shrug — and that indifference is becoming the defining feature of the stock's 2026 trajectory. Despite what the buyout firm describes as a decisive operational turnaround in the first half, the share price continues to drift, leaving investors to weigh a pipeline of promised catalysts against a persistent valuation discount.

The headline numbers from the interim results, released on Tuesday of last week, look sobering at first glance. Adjusted net income collapsed to €6 million in the first six months of 2026, down from €70 million in the same period a year earlier. The explanation, however, has less to do with deteriorating operations than with a base effect: the prior-year figure was flattered by badwill gains and the exit of Steyr, one-off items that have no equivalent in the current period.

Strip those out, and the underlying picture is markedly brighter. Adjusted EBITDA swung to €67 million from a negative €89 million — a swing of more than €150 million that management points to as evidence the restructuring model is finally delivering. Group revenue held steady at €3.4 billion, and the board reaffirmed its full-year guidance, promising a pronounced acceleration in the second half.

Two acquisitions to do the heavy lifting

That acceleration rests largely on two transactions now being folded into the portfolio. The full consolidation of Nordgas Solutions and the completion of the NexPoint acquisition — which brought in the ETP business bought from SABIC — are expected to push the Chemicals & Materials segment past €2 billion in revenue. The integration was completed during the third quarter.

The acquisition machine has not stopped there. Roughly three weeks ago, Mutares closed the purchase of Magna International's car-top systems business, a deal aimed at strengthening the Automotive & Mobility segment. The share price has shed around 3.7 percent since that announcement, a pattern that also followed the Free2move acquisition unveiled about a month ago, which has cost shareholders 2.4 percent.

The exit that could shift the narrative

While the buy-side of the model keeps churning, the sell-side is where the next major test lies. CIO Johannes Laumann has said the planned divestment of NEM should close in the third quarter of 2026 and could generate proceeds of more than €100 million. For a firm built on acquiring, restructuring and profitably disposing of companies, that kind of exit cash is central — not just for credibility, but for balance-sheet stability.

There is also a smaller deal in the works: the acquisition of a Czech chemicals unit from Synthomer, which Mutares aims to finalize in the third quarter. Purchase price and revenue contribution have not been disclosed.

Covenants restored, but questions linger

One quiet but significant development for bondholders: Mutares reported full compliance with its bond covenants as of June 30, easing financing pressure after a period in which its liquidity position had become a talking point.

That relief has not silenced all concerns. Discussions in financial forums and media over the past week have circled around potential writedown requirements at Lapeyre, the French retail subsidiary, even as expectations build for exits at Magirus and Efecec. The juxtaposition — possible impairment charges on one side, anticipated disposal gains on the other — continues to frame the debate over what the portfolio is actually worth.

A stock that refuses to join the party

The equity market, for now, remains unpersuaded. The shares closed Friday at €25.95, up 1.2 percent on the day, but that leaves them 3.7 percent lower over seven days and 14 percent down since the start of the year. At roughly 26 percent below the 52-week high of €35.15 set in mid-January, the stock is trading with a relative strength index near 38, a level that often signals oversold conditions.

The central question for investors is whether the promised exits and the consolidation of recent acquisitions will translate into the operational inflection management has flagged for the second half. The next opportunity to test that thesis comes on November 19, when Mutares hosts an investor day in London — a forum where the market will be looking for evidence that the turnaround is structural rather than episodic.